Aimed at minimizing or removing
oral leukoplakia lesions.
About us
Bio-Convert is a Denmark based biotech company developing a novel proprietary mucoadhesive oral formulation (named QR-02) designed to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia (OLK), an outcome that would mark a significant breakthrough in oral medicine.
- No approved therapies currently exist for OLK – Bio-Convert will become first-movers in developing the only approved drug for OLK.
- Surgery is the primary alternative, often associated with significant morbidity.
- Untreated, OLK can progress to oral cancer.
Mission
Bio-Converts mission is to develop the preferred treatment for oral leukoplakia. Our innovative therapeutic agent, QR-02, uses a novel drug delivery technology, that enables more precise, effective and efficient treatment.
QR-02 holds
huge potential
to become a future treatment of
oral leukoplakia
QR-02 holds huge potential to become a future treatment of oral leukoplakia
Bio-Convert have identified a novel drug delivery technology, that we believe holds significant potential to become the preferred future treatment of oral leukoplakia (OL) using our unique gel, QR-02. The gel is applied directly to the lesions in the mouth. The treatment is intended to reduce/remove the OL lesions, and it will facilitate surgical procedure and improve, and reduce the malign conversion rate, lowering the risk of them turning into cancer.
